CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting
Open Access
- 1 January 2021
- journal article
- review article
- Published by Elsevier in Neuroscience
- Vol. 453, 301-311
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Research and Innovation in Romania (7PFE/16.10.2018)
This publication has 137 references indexed in Scilit:
- CD36 in the periphery and brain synergizes in stroke injury in hyperlipidemiaAnnals of Neurology, 2012
- Polymorphism of the CD36 Gene and Cardiovascular Risk Factors in Patients with Coronary Artery Disease Manifested at a Young AgeBiochemical Genetics, 2011
- A High Content Drug Screen Identifies Ursolic Acid as an Inhibitor of Amyloid β Protein Interactions with Its Receptor CD36Journal of Biological Chemistry, 2011
- Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cellsJournal of Clinical Investigation, 2011
- Parkin reinvents itself to regulate fatty acid metabolism by tagging CD36Journal of Clinical Investigation, 2011
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2010
- Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau PathologyNeuropsychopharmacology, 2010
- Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterolHuman Molecular Genetics, 2008
- ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD StudyArchives of Neurology, 2006
- CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolismJournal of Clinical Investigation, 2001